Artelo Biosciences Inc at Ladenburg Thalmann Healthcare Conference Transcript
Welcome everyone to the Ladenburg Thalmann 2022 Healthcare Conference. My name is Michael Higgins, Managing Director and Senior Biotech Analyst. Thank you all for joining us. I'd be remiss to not remember our friends down in Florida that are going through devastation right now. Our thoughts and prayers are with all of you. Again, thank you for joining us in our conference.
To start us off this morning, first one is Artelo Biosciences, a company I've covered for a few years now. San Diego-based biotech developing therapeutics that target endogenous signaling pathways including the endocannabinoid system. The company has three main assets that we'll be reviewing today. They all target large market opportunities.
First being ART27.13, a GPCR agonist targeting the cannabinoid receptors 1 and 2. Originally developed by AstraZeneca, it's currently being tested in the Phase 1b/2 for cancer anorexia called the CAReS study. In our fireside chat, we'll be talking mostly about that asset.
Followed by ART26.12, a first-in-class
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
